COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,241 Articles (22,733 medRxiv, 8,508 bioRxiv)

Most recent first Previous |  Page 129: Articles 1281-1290  | Next

Optimal intervention strategies for a new pandemic: The case of Covid-19
Holden, S., Ro, G., Hjort, I.
10.1101/2024.12.04.24318460 — Posted: 2024-12-05
Widespread gene-environment interactions shape the immune response to SARS-CoV-2 infection in hospitalized COVID-19 patients
Randolph, H. E., Aguirre-Gamboa, R., Brunet-Ratnasingham, E., Nakanishi, T., Locher, V., Ketter, E., Brandolino, C., Larochelle, C., Prat, A., Arbour, N., Dumaine, A., Finzi, A., Durand, M., Richards, J. B., Kaufmann, D. E., Barreiro, L. B.
10.1101/2024.12.03.626676 — Posted: 2024-12-04
An accelerating, decreasing phylogenetic trend in SARS-CoV-2 genome compositional heterogeneity during the pandemic
Oliver, J. L., Bernaola Galvan, P., Carpena, P., Perfectti, F., Gomez Martin, C., Castiglione, S., Raia, P., Verdu, M., Moya, A.
10.1101/2024.12.03.625388 — Posted: 2024-12-04
Altered spike dynamics drives immune evasion of SARS-CoV-2
Ugurlu, H., Salminen, P., Yuan, M., Fagerlund, R., Mäkelä, A. R., Zusinaite, E., Kesti, T., Rissanen, I., Merits, A., Wilson, I. A., Saksela, K.
10.1101/2024.12.03.626570 — Posted: 2024-12-04
The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication
Weston, S., Baracco, L., Taylor, L., Scott, A., Kumar, G., Shapiro, P., MacKerell, A. D., Frieman, M. B.
10.1101/2024.12.03.626536 — Posted: 2024-12-04
Risk of Severe Outcomes From COVID-19 in Comorbid Populations in the Omicron Era: A Meta-analysis
Chapman, A., Barouch, D. H., Lip, G. Y. H., Pliakas, T., Polverino, E., Sourij, H., Abduljawad, S.
10.1101/2024.12.02.24317727 — Posted: 2024-12-03
Risk Factors for Suicidal Behavior in Youth and the Impact of SARS-CoV-2 Infection: A Retrospective Case-Control Study
Heslin, K. P., Montero, M., Faraone, S. V., Zhang-James, Y.
10.1101/2024.12.02.24318197 — Posted: 2024-12-03
KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2
Wang, Q., Mellis, I. A., Wu, M., Bowen, A., Gherasim, C., Valdez, R., Shah, J. G., Purpura, L. J., Yin, M. T., Gordon, A., Guo, Y., Ho, D. D.
10.1101/2024.12.02.626472 — Posted: 2024-12-03
A Double Machine Learning Approach for the Evaluation of COVID-19 Vaccine Effectiveness under the Test-Negative Design: Analysis of Quebec Administrative Data
Jiang, C., Talbot, D., Carazo, S., Schnitzer, M. E.
10.1101/2024.11.27.24318065 — Posted: 2024-12-02
Environmental exposures and familial background alter the induction of neuropathology and inflammation after SARS-CoV-2 infection.
Chatterjee, D., Kurup, D., Smeyne, R. J.
10.1101/2024.12.02.626375 — Posted: 2024-12-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).